ID: ALA5279574

Max Phase: Preclinical

Molecular Formula: C13H10N2O2S

Molecular Weight: 258.30

Associated Items:

Representations

Canonical SMILES:  O=C(O)Cn1ccc(-c2nc3ccccc3s2)c1

Standard InChI:  InChI=1S/C13H10N2O2S/c16-12(17)8-15-6-5-9(7-15)13-14-10-3-1-2-4-11(10)18-13/h1-7H,8H2,(H,16,17)

Standard InChI Key:  ATKFLTNUWIUJFF-UHFFFAOYSA-N

Associated Targets(non-human)

Aldose reductase 4007 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 258.30Molecular Weight (Monoisotopic): 258.0463AlogP: 2.85#Rotatable Bonds: 3
Polar Surface Area: 55.12Molecular Species: ACIDHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 4.63CX Basic pKa: 1.89CX LogP: 2.92CX LogD: 0.22
Aromatic Rings: 3Heavy Atoms: 18QED Weighted: 0.79Np Likeness Score: -1.70

References

1. Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A..  (2020)  Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.,  207  [PMID:32871344] [10.1016/j.ejmech.2020.112742]

Source